R&D

OmniaMed Co., Ltd. opens up a new paradigm for the development of treatments using Nitric Oxide functionality.

R&D Overview

OmniaMed is developing the next generation of medicine through research to discover the potential of Nitric Oxide.

NO donor: Cancer cell death by the delivery and production of NO

applicable disease: metastatic cancer

Technology with the delivery and production of NO
Development of targeted delivery technology of NO donor
Suppression of metastatic lung cancer and treatment of lymphoma: OM-101-MC
NO scavenger: The overcoming of excessive inflammatory reation and improving fucntion of immune cells.

applicable disease: solid tumor/ rheumatoid arthritis/ osteroarthrosis/ inflammtory bowel disease

Technology that maximizes treatment effectiveness of cancer/inflammatory drugs by removing NO
Control cancer microimmune environment
Immuno-cancer drug combinations
(Immune Gate Inhibitors, CAR T/NK/NKT cell therapy medicine, etc.) : OM-202-SC
Controlling the inflammatory immune environment
Medicines used for inflammatory diseases : OM-202-SM
Rheumatoid arthritis first-in-class medication : OM-201-RA
Treatment for colorectal cancer and inflammatory bowel disease : OM-202-IBD